biotech / news / / MarketScreener
AstraZeneca outlined plans to invest 300 million pounds ($405.5 million) in the U.K. The move reverses AstraZeneca's decision to pause planned investments in its home country last year.
AstraZeneca is investing £300 million in the UK after pausing local investment last year.
KEY POINTS
- The renewed UK investment follows a drug-pricing deal between the UK and US to boost pharma spending.
- AstraZeneca's oncology unit now makes up 44% of total revenue and dominates its late-stage pipeline.
- Company revenue and core earnings for Q1 both exceeded analyst forecasts, driven by cancer drug demand.
- UK pharma investment commitments since December are £1.575 billion, spurred by the UK-US pharma deal.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →